KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Other Non-Current Liabilities (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Other Non-Current Liabilities for 15 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 28.72% to $3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Dec 2025, down 28.72% year-over-year, with the annual reading at $3.4 million for FY2025, 28.72% down from the prior year.
  • Other Non-Current Liabilities hit $3.4 million in Q4 2025 for Arbutus Biopharma, down from $11.1 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $19.4 million in Q1 2021 to a low of $3.4 million in Q4 2025.
  • Historically, Other Non-Current Liabilities has averaged $8.3 million across 5 years, with a median of $7.7 million in 2023.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 531.84% in 2021 and later tumbled 81.27% in 2022.
  • Year by year, Other Non-Current Liabilities stood at $16.3 million in 2021, then tumbled by 53.79% to $7.5 million in 2022, then increased by 0.92% to $7.6 million in 2023, then crashed by 36.46% to $4.8 million in 2024, then fell by 28.72% to $3.4 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for ABUS at $3.4 million in Q4 2025, $11.1 million in Q3 2025, and $10.8 million in Q2 2025.